Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells

The reasons for the distinct chemoresistance of liposarcomas and their high risk of local recurrence still remain unclear. Depending on the histological subtype of liposarcoma, first-line therapy with the cytostatic agent, doxorubicin, only achieves response rates of approximately 36%. Approximatley...

Descripción completa

Detalles Bibliográficos
Autores principales: HARATI, KAMRAN, DAIGELER, ADRIEN, HIRSCH, TOBIAS, JACOBSEN, FRANK, BEHR, BJÖRN, WALLNER, CHRISTOPH, LEHNHARDT, MARCUS, BECERIKLI, MUSTAFA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867885/
https://www.ncbi.nlm.nih.gov/pubmed/27082154
http://dx.doi.org/10.3892/ijmm.2016.2556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867885/
https://www.ncbi.nlm.nih.gov/pubmed/27082154
http://dx.doi.org/10.3892/ijmm.2016.2556

Ejemplares similares